Navigation Links
Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
Date:11/15/2007

HIV tropism status needed to initiate therapy with Pfizer's recently

approved Selzentry(TM) (Maraviroc), CCR5 antagonist

MALIBU, Calif., Nov. 15 /PRNewswire/ -- Pathway Diagnostics announces that the U.S. Patent & Trademark Office (USPTO) has issued U.S. Patent number 7,294,458 (the '458 patent) entitled "Analysis of HIV-1 Co-receptor Use in the Clinical Care of HIV-1-Infected Patients." Pathway Diagnostics has licensed the '458 patent (with rights to sub-license) from Health Research Incorporated (HRI), Rensselaer, NY for use in the fields of laboratory diagnosis and monitoring. The '458 patent discloses and claims diagnostic methods for monitoring CCR5 and CXCR4 co-receptor use in the treatment of human immunodeficiency virus (HIV) infection. The '458 patent also claims monitoring CXCR4-specific strain suppression in HIV-positive individuals undergoing highly active anti-retroviral therapy (HAART). Pathway has also obtained licensing rights from HRI for related patent applications, that together with the '458 patent, form the technical foundation of Pathway's SensiTrop HIV tropism assay.

"The patented technology underlying Pathway's SensiTrop assay is a significant innovation that enables HIV treating physicians to select the appropriate treatment for patients using a proprietary molecular assay that is fast and affordable. Pathway's partners have recognized the strength of Pathway's patent portfolio and the importance of these patents when testing CCR5 and CXCR4 co-receptor use for HIV therapy," stated Walter Narajowski, CEO of Pathway Diagnostics.

About HIV Co-receptor tropism and the SensiTrop(TM) assay

The ability of the HIV virus to infect different cell types utilizing different cell surface receptors is referred to as HIV co-receptor tropism. One type of HIV that utilizes the CCR5 co-receptor has been shown to be blocked by CCR5 antagonist drugs such as Selzentry. A different type of HIV that utilizes the CXCR4
'/>"/>

SOURCE Pathway Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
9. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
10. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... NEW YORK , May 4, 2015 /PRNewswire-USNewswire/ ... system for granted. But for certain infants with ... and death are stark consequences of their impaired ... Langone Medical Center have identified an important role ... infection resulting from Mycobacterium tuberculosis, the bacterium causing ...
(Date:5/4/2015)... JSS Medical Research Inc., a Montreal based ... of Max Neeman International (MNI), with head office in ... Ahmedabad, Bangalore , Chennai ... regional office is located North Carolina, USA . ... equity investment transaction into JSS with Capital Croissance PME (CCPME), a ...
(Date:5/4/2015)... BOSTON , May 4, 2015 ... development of novel therapies for neurological and neuropsychiatric ... has initiated dosing of Alzheimer,s patients in a ... candidate, GC021109, a compound developed as a potential ... disease is innovative in that it both promotes ...
(Date:5/4/2015)... 4, 2015  Traverse Biosciences announced today that ... development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: ... TRB-N0224 for the treatment and control of periodontal ... Traverse Biosciences has also granted Aratana an exclusive ... control of periodontal disease in companion animals, inclusive ...
Breaking Biology Technology:Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4
... Jan. 28 Bion Environmental Technologies, ... on Monday, January 26, 2009, the Pennsylvania Infrastructure ... to Bion PA 1, LLC (a wholly-owned subsidiary ... the loan will be used to construct Bion,s ...
... quarter EPS of $0.44 -- increase of 110% from prior year ... Corporation (Nasdaq: KNSY ), a leading medical technology company ... medical procedures, today reported the results for its second quarter and ... , Record ...
... , - Guests Will Bounce ... Staying healthy in these stressful times ... Health Retreats early in 2009 may provide,participants with the impetus ... A key component of the retreat will ...
Cached Biology Technology:Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project 2Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project 3Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project 4Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 2Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 3Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 4Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 5Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 6Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 7Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 8Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 9Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 10Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 11Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 12Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 13Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 14Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 15Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 16Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 17Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results 18New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/2/2015)... At its 2015 ACMG Annual Clinical Genetics ... the American College of Medical Genetics and Genomics (ACMG) ... Board.  Members of the ACMG Board of Directors serve ... advancing its policies and programs. ACMG is the national ... an eventful time in medical genetics and genomics.  We ...
(Date:3/31/2015)... 2015  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ... Software Defined Network Architecture (ET Software DNA® 2.0) platforms ... approximately $20.4 million for the year ended December 31, ... the year ended December 31, 2013. ... completed its multi-year transition away from its legacy landline ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... are reporting that a technique used in the search for ... discover new, environmentally friendly materials for fighting global warming. Such ... dioxide from industrial smokestacks and other fixed sources before it ... journal Energy & Fuels . Michael Drummond and ...
... an advance with overtones of Star Trek phasers and other ... an internal on-off "switch" that paralyzes animals when exposed to ... when the light is turned off. When exposed to ordinary ... appears in the Journal of the American Chemical Society ...
... of Pennsylvania studying oocytes in mice, the immature egg ... behavior in microRNA, or miRNA, activity that may be ... pluripotent blastomeres of the embryo. MicroRNAs are a member ... matter of the biological world. MicroRNAs imperfectly pair ...
Cached Biology News:Penn biologists determine microRNA activity is suppressed in mouse ovum 2
... Source: Crotalus adamanteus venom Description: ... widely used in studying nucleic ... . It hydrolyzes 5'-mononucleotides from ... . Phosphodiesterase I cleaves ADP-ribosylated ...
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... digitonin and digoxin. Physical form: Lyophilized powder containing ... 0.06% NaCl Preparation Note: Sodium iodide extracted fraction ... 19, 755 (1965). Unit Definition: One unit ... ATP per min at pH 7.4 at 37 ...
... introduced the highly potent TURBO DNase (patent pending) ... was set in DNA removal capabilities. TURBO DNase ... that is much more efficient than wild type ... unwanted DNA. TURBO DNase binds DNA substrates 6-fold ...
Biology Products: